- Disease: Post COVID-19 condition
- Study type: Randomised Clinical Trial, Treatment
- Study type descriptors: Interventional
- Objective: To evaluate the efficacy and safety of Temelimab as a treatment for post COVID-19 syndrome neuropsychiatric symptoms in patients who had severe acute SARS-CoV-2 infection but did not undergo intensive care treatment during the acute period
- Number of participants enrolled: 203
- Study enrolling from to
- Study includes follow-up for 6 months
Sites (7)
- Fundació ACE (Barcelona, Spain)
- Agostino Gemelli University Polyclinic (Rome, Italy)
- Policlinico Tor Vergata (Rome, Italy)
- Azienda Ospedaliero-Universitaria di Modena (Modena, Italy)
- Hospital Universitario Quirónsalud Madrid (Madrid, Spain)
- Blue Healthcare (Madrid, Spain)
- Hospital of Vipiteno (Sterzing, Italy)
Study Data
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Outpatient clinic
- SARS-CoV-2
- Post COVID-19 condition
- Pharmacological intervention
- Monoclonal antibodies
- Temelimab
External Links
Other information
Funders/Sponsors:
- GeNeuro SA
The information was provided with the aid of the study investigators
If you would like to contact the Principal Investigator of the study please email: ccb@ateneo.univr.it
The data is updated up to